Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination

Richard Aspinall, Jeffrey Pido-Lopez, Nesrina Imami, Sian M. Henson, Pa Tamba Ngom, Michel Morre, Henk Niphuis, Ed Remarque, Brigitte Rosenwirth, Jonathan L. Heeney

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Old age is accompanied by an increased incidence of infection and poorer responses to vaccination. In this proof of principle study, old female rhesus macaques (aged 18.5 to 23.9 years) were treated with recombinant simian interleukin-7 (IL-7) or saline, according to a two-phase regime. Treatment was not associated with bone loss as fudged by plasma carboxy terminal telopeptide of type I collagen (ICTP) levels, nor with neutropenia. IL-7-treated animals showed an increase in the number of blood CD4+CD3+ and CD8+CD3+ T cells after both phases of treatment and a transient increase in the number of naïve (CD62L+CD45RA +) T cells for both CD4+ and CD8+ subsets after only the first treatment. Increases in TREC levels per T cell followed both phases of treatment, but were more prolonged after the second phase. Following vaccination with inactivated influenza strain A/PR/8/34, hemagglutination inhibition assays showed that half of the IL-7-treated animals showed a greater than eight-fold increase in antibody titer following the first challenge with the vaccine. In addition IL-7-treated animals showed higher, numbers of central memory CD8+ T cells compared to pretreatment levels with numbers greater than in the saline-treated group. Animals with the highest hemagglutination inhibition titers and the best proliferation against flu antigen were among those with the highest TREC per T cell levels after the second phase of treatment. Treatment of the elderly with IL-7 may provide an effective therapy to improve the immune system.

Original languageEnglish
Pages (from-to)5-17
Number of pages13
JournalRejuvenation Research
Volume10
Issue number1
DOIs
Publication statusPublished - Mar 2007
Externally publishedYes

Fingerprint

Interleukin-7
Macaca mulatta
Human Influenza
Vaccination
T-Lymphocytes
Hemagglutination
Therapeutics
Collagen Type I
Neutropenia
Immune System
Vaccines
Antigens
Bone and Bones
Antibodies
Incidence
Infection

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology

Cite this

Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination. / Aspinall, Richard; Pido-Lopez, Jeffrey; Imami, Nesrina; Henson, Sian M.; Ngom, Pa Tamba; Morre, Michel; Niphuis, Henk; Remarque, Ed; Rosenwirth, Brigitte; Heeney, Jonathan L.

In: Rejuvenation Research, Vol. 10, No. 1, 03.2007, p. 5-17.

Research output: Contribution to journalArticle

Aspinall, R, Pido-Lopez, J, Imami, N, Henson, SM, Ngom, PT, Morre, M, Niphuis, H, Remarque, E, Rosenwirth, B & Heeney, JL 2007, 'Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination' Rejuvenation Research, vol. 10, no. 1, pp. 5-17. https://doi.org/10.1089/rej.2006.9098
Aspinall, Richard ; Pido-Lopez, Jeffrey ; Imami, Nesrina ; Henson, Sian M. ; Ngom, Pa Tamba ; Morre, Michel ; Niphuis, Henk ; Remarque, Ed ; Rosenwirth, Brigitte ; Heeney, Jonathan L. / Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination. In: Rejuvenation Research. 2007 ; Vol. 10, No. 1. pp. 5-17.
@article{86d39493eced4f37a485afe6237985e0,
title = "Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination",
abstract = "Old age is accompanied by an increased incidence of infection and poorer responses to vaccination. In this proof of principle study, old female rhesus macaques (aged 18.5 to 23.9 years) were treated with recombinant simian interleukin-7 (IL-7) or saline, according to a two-phase regime. Treatment was not associated with bone loss as fudged by plasma carboxy terminal telopeptide of type I collagen (ICTP) levels, nor with neutropenia. IL-7-treated animals showed an increase in the number of blood CD4+CD3+ and CD8+CD3+ T cells after both phases of treatment and a transient increase in the number of na{\"i}ve (CD62L+CD45RA +) T cells for both CD4+ and CD8+ subsets after only the first treatment. Increases in TREC levels per T cell followed both phases of treatment, but were more prolonged after the second phase. Following vaccination with inactivated influenza strain A/PR/8/34, hemagglutination inhibition assays showed that half of the IL-7-treated animals showed a greater than eight-fold increase in antibody titer following the first challenge with the vaccine. In addition IL-7-treated animals showed higher, numbers of central memory CD8+ T cells compared to pretreatment levels with numbers greater than in the saline-treated group. Animals with the highest hemagglutination inhibition titers and the best proliferation against flu antigen were among those with the highest TREC per T cell levels after the second phase of treatment. Treatment of the elderly with IL-7 may provide an effective therapy to improve the immune system.",
author = "Richard Aspinall and Jeffrey Pido-Lopez and Nesrina Imami and Henson, {Sian M.} and Ngom, {Pa Tamba} and Michel Morre and Henk Niphuis and Ed Remarque and Brigitte Rosenwirth and Heeney, {Jonathan L.}",
year = "2007",
month = "3",
doi = "10.1089/rej.2006.9098",
language = "English",
volume = "10",
pages = "5--17",
journal = "Rejuvenation Research",
issn = "1549-1684",
publisher = "Mary Ann Liebert",
number = "1",

}

TY - JOUR

T1 - Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination

AU - Aspinall, Richard

AU - Pido-Lopez, Jeffrey

AU - Imami, Nesrina

AU - Henson, Sian M.

AU - Ngom, Pa Tamba

AU - Morre, Michel

AU - Niphuis, Henk

AU - Remarque, Ed

AU - Rosenwirth, Brigitte

AU - Heeney, Jonathan L.

PY - 2007/3

Y1 - 2007/3

N2 - Old age is accompanied by an increased incidence of infection and poorer responses to vaccination. In this proof of principle study, old female rhesus macaques (aged 18.5 to 23.9 years) were treated with recombinant simian interleukin-7 (IL-7) or saline, according to a two-phase regime. Treatment was not associated with bone loss as fudged by plasma carboxy terminal telopeptide of type I collagen (ICTP) levels, nor with neutropenia. IL-7-treated animals showed an increase in the number of blood CD4+CD3+ and CD8+CD3+ T cells after both phases of treatment and a transient increase in the number of naïve (CD62L+CD45RA +) T cells for both CD4+ and CD8+ subsets after only the first treatment. Increases in TREC levels per T cell followed both phases of treatment, but were more prolonged after the second phase. Following vaccination with inactivated influenza strain A/PR/8/34, hemagglutination inhibition assays showed that half of the IL-7-treated animals showed a greater than eight-fold increase in antibody titer following the first challenge with the vaccine. In addition IL-7-treated animals showed higher, numbers of central memory CD8+ T cells compared to pretreatment levels with numbers greater than in the saline-treated group. Animals with the highest hemagglutination inhibition titers and the best proliferation against flu antigen were among those with the highest TREC per T cell levels after the second phase of treatment. Treatment of the elderly with IL-7 may provide an effective therapy to improve the immune system.

AB - Old age is accompanied by an increased incidence of infection and poorer responses to vaccination. In this proof of principle study, old female rhesus macaques (aged 18.5 to 23.9 years) were treated with recombinant simian interleukin-7 (IL-7) or saline, according to a two-phase regime. Treatment was not associated with bone loss as fudged by plasma carboxy terminal telopeptide of type I collagen (ICTP) levels, nor with neutropenia. IL-7-treated animals showed an increase in the number of blood CD4+CD3+ and CD8+CD3+ T cells after both phases of treatment and a transient increase in the number of naïve (CD62L+CD45RA +) T cells for both CD4+ and CD8+ subsets after only the first treatment. Increases in TREC levels per T cell followed both phases of treatment, but were more prolonged after the second phase. Following vaccination with inactivated influenza strain A/PR/8/34, hemagglutination inhibition assays showed that half of the IL-7-treated animals showed a greater than eight-fold increase in antibody titer following the first challenge with the vaccine. In addition IL-7-treated animals showed higher, numbers of central memory CD8+ T cells compared to pretreatment levels with numbers greater than in the saline-treated group. Animals with the highest hemagglutination inhibition titers and the best proliferation against flu antigen were among those with the highest TREC per T cell levels after the second phase of treatment. Treatment of the elderly with IL-7 may provide an effective therapy to improve the immune system.

UR - http://www.scopus.com/inward/record.url?scp=33947413409&partnerID=8YFLogxK

U2 - 10.1089/rej.2006.9098

DO - 10.1089/rej.2006.9098

M3 - Article

VL - 10

SP - 5

EP - 17

JO - Rejuvenation Research

JF - Rejuvenation Research

SN - 1549-1684

IS - 1

ER -